Alessandra Ferrajoli

Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 258 publications

Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study.

Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study.

Journal: Cancers

Published: June 04, 2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: May 06, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: December 10, 2025

Is CLL curable?

Is CLL curable?

Journal: HemaSphere

Published: November 06, 2025

Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.

Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: October 22, 2025

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Journal: Blood cancer discovery

Published: October 18, 2025

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Journal: Cancer medicine

Published: October 12, 2025

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Journal: Cancer

Published: July 24, 2025

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Journal: Blood neoplasia

Published: June 18, 2025

Best Supportive Care for Patients with Chronic Lymphocytic Leukemia: Relevance of Cancer Screening and Immunizations.

Best Supportive Care for Patients with Chronic Lymphocytic Leukemia: Relevance of Cancer Screening and Immunizations.

Journal: Cancers

Published: May 31, 2025

Showing 1-12 of 258

Last Updated: 09/26/2026